Robert A Carr
Overview
Explore the profile of Robert A Carr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Miller J, Beig A, Carr R, Webster G, Dahan A
Mol Pharm
. 2012 Jan;
9(3):581-90.
PMID: 22280478
We have recently reported the interplay between apparent aqueous solubility and intestinal membrane permeability, showing the trade-off between the two when using cyclodextrin- and surfactant-based systems as solubility-enabling formulations. In...
12.
Miller J, Beig A, Krieg B, Carr R, Borchardt T, Amidon G, et al.
Mol Pharm
. 2011 Aug;
8(5):1848-56.
PMID: 21800883
Surfactants are routinely employed to increase the apparent aqueous solubility of poorly soluble drugs. Yet the impact of micellar solubilization on the intestinal membrane permeability of a lipophilic drug is...
13.
Chin C, Carr R, Llano D, Barret O, Xu H, Batis J, et al.
J Pharmacol Exp Ther
. 2010 Dec;
336(3):716-23.
PMID: 21172907
Neuronal acetylcholine nicotinic receptors (nAChRs) are targets for the development of novel treatments of brain diseases. However, adverse effects (for example, emesis or nausea) associated with high drug maximal exposures...
14.
Gao Y, Carr R, Spence J, Wang W, Turner T, Lipari J, et al.
Mol Pharm
. 2010 Aug;
7(5):1516-26.
PMID: 20715778
Physiologically based pharmacokinetic (PBPK) modeling tools have become an integral part of the modern drug discovery-development process. However, accurate PK prediction of enabling formulations of poorly soluble compounds by applying...
15.
Baker L, Rowinsky E, Mendelson D, Humerickhouse R, Knight R, Qian J, et al.
J Clin Oncol
. 2008 Nov;
26(34):5583-8.
PMID: 18981463
Purpose: Sarcomas are among the most proangiogenic malignancies in preclinical models. Phase I study results for ABT-510, which inhibits angiogenesis via a novel thrombospondin-mimetic mechanism, suggested activity in soft tissue...
16.
Xiong H, Carr R, Locke C, Katz D, Achari R, Doan T, et al.
J Clin Pharmacol
. 2007 Mar;
47(4):423-9.
PMID: 17389551
The effect of rifampin, a cytochrome P450 3A4 inducer, on the pharmacokinetics of atrasentan was assessed in 12 healthy male subjects in an open-label study. Single doses of atrasentan 10...
17.
Carr R, Andre A, Chen P, Grabowski B, Chang M, Locke C, et al.
Nephron Clin Pract
. 2006 Mar;
103(3):c100-5.
PMID: 16534233
Background/aims: Paricalcitol is highly protein bound, extensively metabolized and eliminated primarily by hepatobiliary excretion. This study was designed to determine if hepatic disease alters the pharmacokinetics or affects the safety...
18.
Hoekstra R, de Vos F, Eskens F, Gietema J, van der Gaast A, Groen H, et al.
J Clin Oncol
. 2005 Jul;
23(22):5188-97.
PMID: 16051960
Purpose: ABT-510 is an angiogenesis inhibitor derived from thrombospondin-1, a naturally occurring inhibitor of angiogenesis. We investigated ABT-510, which was administered subcutaneously in patients with advanced solid malignancies, to assess...
19.
Ryan C, Vogelzang N, Vokes E, Kindler H, Undevia S, Humerickhouse R, et al.
Clin Cancer Res
. 2004 Jul;
10(13):4406-11.
PMID: 15240529
Purpose: Atrasentan is an orally bioavailable selective antagonist of the endothelin receptor ET(A). Due to the potential activity of this agent against prostate cancer, the majority of subjects enrolled in...
20.
Zonnenberg B, Groenewegen G, Janus T, Leahy T, Humerickhouse R, Isaacson J, et al.
Clin Cancer Res
. 2003 Aug;
9(8):2965-72.
PMID: 12912943
Purpose: Evidence suggests that endothelin (ET)-1 and its primary receptor, the ET(A) receptor, may contribute to the progression of prostate and other cancers. Atrasentan (ABT-627) is a highly potent, selective...